International Scholarly Research Notices / 2011 / Article / Tab 1

Research Article

Switching from Intravitreal Ranibizumab to Bevacizumab for Age-Related Macular Degeneration

Table 1

Demographics and characteristics of patients.

PtAgeSexDuration of IVR treatment (months)Number of IVRPrior PDTDuration of IVB treatment (months)Number of IVB

179Female63(+)133
279Female73(−)121
366Female115(−)113
462Male85(+)93
576Female106(−)106
665Female106(−)104
768Male86(−) 116

IVR: intravitreal ranibizumab; PDT: photodynamic therapy; IVB: intravitreal bevacizumab.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.